Medication info
Dapagliflozin Propanediol Hydrate / Sitagliptin Phosphate Hydrate / Metformin Hydrochloride Colloidal Silicon Dioxide Extended-Release Tablet 5/50/1000 mg

Dapagliflozin Propanediol Hydrate / Sitagliptin Phosphate Hydrate / Metformin Hydrochloride Colloidal Silicon Dioxide Extended-Release Tablet 5/50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›6.15mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Yellow, biconvex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202302020 · Approved 2023.06.30 · Insurance code 671807750

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is dapagliflozin 10 mg and sitagliptin 100 mg; the dose of metformin hydrochloride extended-release, not exceeding 2000 mg, is determined based on each patient's current treatment regimen, efficacy, and tolerability. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the metformin hydrochloride dose needs adjustment, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/500 mg, 5/50/750 mg, or 5/50/1000 mg extended-release tablets should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should be dapagliflozin 10 mg, sitagliptin 100 mg, and the current dose of metformin hydrochloride, or a therapeutically similar dose. For patients switching to this medicine from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine is the patient's existing dose of each component. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because changes may affect glycemic control, any changes in treatment for patients with type 2 diabetes should be made under close monitoring. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Patients with renal impairment The efficacy and safety of this medicine depend on renal function, and dose adjustment according to renal function is necessary. Therefore, it is recommended that renal function be assessed before and periodically after administration of this medicine. No dose adjustment is necessary in patients with mild renal impairment. When the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided the patient tolerates it well and has no other condition that could increase the risk of lactic acidosis. The starting dose of metformin hydrochloride extended-release is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood glucose in patients with type 2 diabetes when used in conjunction with dapagliflozin, sitagliptin, and metformin. It is used to effectively lower blood glucose levels, complementing dietary and exercise therapies, thereby improving patients' blood glucose management for maintaining a healthy lifestyle.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is dapagliflozin 10 mg and sitagliptin 100 mg; the dose of metformin hydrochloride extended-release, not exceeding 2000 mg, is determined based on each patient's current treatment regimen, efficacy, and tolerability. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the metformin hydrochloride dose needs adjustment, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/500 mg, 5/50/750 mg, or 5/50/1000 mg extended-release tablets should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should be dapagliflozin 10 mg, sitagliptin 100 mg, and the current dose of metformin hydrochloride, or a therapeutically similar dose. For patients switching to this medicine from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine is the patient's existing dose of each component. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because changes may affect glycemic control, any changes in treatment for patients with type 2 diabetes should be made under close monitoring. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Patients with renal impairment The efficacy and safety of this medicine depend on renal function, and dose adjustment according to renal function is necessary. Therefore, it is recommended that renal function be assessed before and periodically after administration of this medicine. No dose adjustment is necessary in patients with mild renal impairment. When the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided the patient tolerates it well and has no other condition that could increase the risk of lactic acidosis. The starting dose of metformin hydrochloride extended-release is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.

Precautions

This medication contains sitagliptin, dapagliflozin, and metformin components and is used for diabetes treatment. Firstly, the sitagliptin component can rarely cause serious allergic reactions such as anaphylaxis or skin disorders, so if any abnormal symptoms arise, you should consult a doctor immediately. Also, acute pancreatitis may occur, so symptoms such as abdominal pain should be closely monitored, and if pancreatitis is suspected, the medication should be discontinued. Next, the dapagliflozin component works by increasing the excretion of glucose through urine, lowering blood glucose levels. This may increase the risk of genital and urinary tract infections, so appropriate treatment is necessary if infection symptoms occur. Additionally, hypotension or renal impairment may occur due to decreased fluid volume; therefore, caution should be exercised, especially in individuals with reduced renal function or the elderly. In severe cases, serious infections such as necrotizing fasciitis may occur, so immediate treatment is required if related symptoms appear. If blood glucose control is inadequate, a metabolic disorder called ketoacidosis may develop; hence, symptoms such as vomiting, abdominal pain, and difficulty breathing should be closely monitored. The metformin component poses a risk of lactic acidosis, a rare but fatal metabolic complication in patients with impaired liver and kidney function, necessitating regular renal function tests. It also carries the risk of gastrointestinal disorders, vitamin B12 deficiency, and hypoglycemia, particularly when used in conjunction with other hypoglycemic agents or alcohol. This medication should not be administered to patients with severely impaired renal function, acute heart failure, acute myocardial infarction, severe liver disease, or pregnant women. Moreover, patients scheduled for surgery or those with severe infections should temporarily discontinue the medication. During use, symptoms of hypoglycemia, infection, abdominal pain, skin rash, and reduced fluid volume should be monitored closely, and if any abnormalities occur, immediate consultation with medical personnel is essential. Regular tests of kidney and liver function should be conducted, and particularly elderly patients or those with impaired renal function require closer monitoring.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hemorrhagic pancreatitis
  • necrotizing pancreatitis
  • lactic acidosis
  • hypoglycemia
  • vulvovaginitis
Show 90 more
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • perineal necrosis
  • decreased fluid volume
  • polydipsia
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • interstitial nephritis
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased serum creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • rash
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • paresthesia
  • cerebral infarction
  • nerve compression
  • acute pyelonephritis
  • asthenia
  • pain
  • keratitis
  • chronic obstructive pulmonary disease
  • hemoptysis
  • cerebral hemorrhage
  • peripheral artery occlusion
  • angina
  • myocardial infarction
  • bile duct stones
  • cholangitis
  • alcoholic liver cirrhosis
  • depression
  • suicide attempt
  • gastric adenocarcinoma
  • anaphylactic reaction
  • headache
  • upper respiratory tract infection
  • nasopharyngitis
  • peripheral edema
  • diarrhea
  • abdominal pain
  • vomiting
  • indigestion
  • urinary retention
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • decreased appetite
  • headache
  • pruritus
  • urticaria
  • arthralgia
  • musculoskeletal pain
  • limb pain
  • muscle weakness
  • myalgia
  • osteoarthritis
  • ligament sprain
  • diabetic retinopathy
  • cough
  • dyspnea
  • orthostatic hypotension
  • palpitations
  • insomnia
  • fatty liver
  • gallbladder polyps
  • tinnitus
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • anorexia
  • erythema
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, biconvex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.